Tenelia
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Tenelia (teneligliptin; Mitsubishi Tanabe) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut. Inhibition of DPP-IV augments the amount of active GLP-1, which in turn triggers increased insulin secretion from the pancreas in a glucose-dependent manner and suppresses the release of glucagon, resulting in lowered blood glucose levels. Generic alogliptin was approved by the US Food and Drug Administration in April 2016.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Tenelia : Diabetes type 2
LIST OF FIGURES
5 Figure 1: Tenelia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
6 Table 1: Tenelia sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Nesina 
Sign up to the